MedTrace Logo

Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis

NCT00556179 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2009-01-22

No results posted yet for this study

Summary

The purpose of this study is to demonstrate if the use of Dermacyd can avoid the recurrence of bacterial vaginosis after three months of the standard treatment.

Conditions

  • Bacterial Vaginosis

Interventions

DRUG

Lactoserum (Dermacyd Femina®)

Once a day during three months

Sponsors & Collaborators

Principal Investigators

  • Jaderson Lima · Sanofi-aventis administrative office Brazil

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00556179 on ClinicalTrials.gov